Target
CEACAM5
5 products, 6 indications
Indications
NSCLC (1 products)
metastatic non-small cell lung cancer (1 products)
advanced non-squamous NSCLC (1 products)
recurrent prostate cancer (1 products)
advanced, metastatic solid tumors (1 products)
glioblastoma (1 products)
Loading...
3 drugs
11 abstracts
Abstract
First-in-human trial of M9140, an anti-CEACAM5 antibody drug conjugate (ADC) with exatecan payload, in patients (pts) with metastatic colorectal cancer (mCRC).Org: Merck Santé S.A.S., Merck Specialities Pvt. Ltd., Merck Institute of Pharmacometrics, The Healthcare Business of Merck KGaA, Next Oncology Virginia and Virginia Cancer Specialists,
Abstract
An open-label phase 1 study to investigate SGNCEACAM5C/SAR445953 in adults with advanced solid tumors (SGNCEA5C-001).Org: START San Antonio, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Mayo Clinic Cancer Center, Beth Israel Deaconess Medical Center, START Mountain Region,
Abstract
EVEREST-1: A seamless phase 1/2 study of A2B530, a carcinoembryonic antigen (CEA) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH).Org: A2 Biotherapeutics, Inc., H. Lee Moffitt Cancer Center and Research Institute, Mayo Clinic, NYU Langone Health, New York, NY, Washington University in St. Louis,
Abstract
The SURVIVE study: Liquid biopsy guided surveillance after intermediate- to high-risk early breast cancer.Org: Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany, Department of Women's Health, University of Tübingen, Tübingen, Germany, Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany, Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany, Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany,
Abstract
Phase I trial of hypoxia-responsive CEA CAR-T cell therapy in patients with heavily pretreated solid tumor via intraperitoneal or intravenous transfusion.Org: Chongqing Precision Biotech Co., Ltd.,
Abstract
SCORE: A multisite randomised controlled trial evaluating shared care for colorectal cancer survivors.Org: Department of General Practice and Centre for Cancer Research, NHMRC Clinical Trials Centre, Centre for Health Economics Research and Evaluation, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Wellness and Research Centre,
Abstract
A novel three-biomarker signature (CA-62, CEA, CYFRA 21-1) and early-stage NSC lung cancer detection.Org: UCM Technologies Inc., Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, I.M.Sechenov First Moscow Medical University, IM Sechenov First Moscow State Medical University, Pacific Biosciences Research Centre,
Abstract
TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab vs best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum.Org: Gustave-Roussy Cancer Campus, Institut Claudius Regaud, IUCT-Oncopole Toulouse, Institut Paoli Calmettes, Biostatistic Unit, IRCCS Humanitas Research Hospital, Rozzano (Milano), Italy,
Abstract
Plasma-based methylated SEPTIN9 circulating tumor DNA to predict progression-free and overall survival in metastatic colorectal cancer.Org: Cedars-Sinai Medical Center,
Abstract
Phase 1/2 study of tusamitamab ravtansine in patients with advanced solid tumors: Pooled safety analysis of corneal adverse events.Org: Gustave Roussy Département d'Organisation du Parcours Patient, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Institut Bergonié, Aix Marseille University - Assistance Publique Hopitaux De Marseille, Université Paris Saclay,
Abstract
"Armed" CEA CAR-T with a SIRPγ-CD28 chimeric co-receptor to exhibit the enhanced antitumor activity in preclinical study of colorectal cancer.Org: Chongqing Precision Biotech Co., Ltd.,
Drug
tusamitamabDrug
CEA vaccineDrug
VG2025